JAMB issues strict warnings for the 2026 UTME registration, prohibiting biodata changes, double registration, and use of ...
Hosted on MSN
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel), during two ...
GERMANTOWN, Md. - Barinthus Biotherapeutics plc (NASDAQ:BRNS) announced Wednesday that its experimental celiac disease treatment VTP-1000 showed promising results in the initial portion of its first ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cabaletta Bio ( (CABA)) has issued an ...
An experimental Ventyx Biosciences drug led to statistically significant reductions in blood levels of a protein that’s an indicator of cardiovascular risk, preliminary Phase 2 results that support ...
-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...
Plus: Elon Musk tried to persuade Mark Zuckerberg to invest in OpenAI This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of ...
At the Bioprocessing Summit in Boston today, Cenk Undey, PhD, recently appointed iCMC Digital Transformation Program Lead at Sanofi, challenged the audience to look “beyond digital” toward a future ...
Plus: Microsoft is trying to fix a major security vulnerability This is today's edition of The Download, our weekday newsletter that provides a daily dose of what's going on in the world of technology ...
INmune Bio Inc. (NASDAQ:INMB) stock is trading higher on Friday, with a session volume of 10.26 million compared to the average volume of 519.5K, per data from Benzinga Pro. On Thursday, INmune Bio ...
The U.S. Food and Drug Administration (FDA) on Wednesday approved Nuvation Bio Inc.’s (NASDAQ:NUVB) Ibtrozi (taletrectinib) for adult patients with locally advanced or metastatic ROS1-positive (ROS1+) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback